Exelixis (EXEL) Stock
Exelixis (EXEL) closed at $68.50 on Nov 17, 2026; its Tenet Score is 74 of 100 against 340 Healthcare peers.
5 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $68.50
- Nov 17, 2026
- Market cap
- $16.6B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- P/E
- 20.2×
- TTM through Jul 3, 2026 · as of close, Nov 16, 2026
- 52-week range
- 39.71 – 73.69
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 74/100
- Solid · 340 Healthcare peers
Industry: Drugs
Exelixis Inc scores 74/100. Solid. Strongest on growth and quality, trading at 20× earnings versus 340 Healthcare peers.
Tenet Score · vs sector
n=340Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✓ Buffett Quality
- ~ Piotroski F-Score
- ✓ Munger Compounders
- ✓ Magic Formula
- ✕ Graham Defensive
- ✕ Lynch GARP
13F flows & insider trades land here.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients wi…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Incyte Corp.INCY | 60 | $24.5B |
| Alnylam Pharmaceuticals IncALNY | 52 | $21.4B |
| Medpace Holdings IncMEDP | 59 | $18.1B |
| Ascendis Pharma A/SASND | 53 | $16.8B |
| Neurocrine Biosciences, Inc.NBIX | 65 | $16.7B |
| Jazz Pharmaceuticals plcJAZZ | 47 | $15.4B |
| Elanco Animal Health IncELAN | 37 | $13.2B |
| Dr. Reddy's Laboratories Ltd.RDY | 45 | $12.3B |
| Bio-Techne CorpTECH | 51 | $11.4B |
| Biomarin Pharmaceutical Inc.BMRN | 43 | $11.2B |
Common questions
What sector and industry is Exelixis in?
Exelixis is in the Healthcare sector and the Drugs industry.
What is Exelixis' Tenet Score?
Exelixis' Tenet Score is 74 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




